Ourobio’s 10-slide teaser deck presents a compelling circular economy play within the biotechnology sector. The company focuses on upcycling dairy industry waste into biodegradable plastic resins and natural colorants through a proprietary single-fermentation process. The deck effectively communicates their technical progress, noting they have reached TRL 3/4 and secured MOUs after 1000+ hours of market discovery. While the deck is strong on vision and technical milestones—citing $400k in bootstrapped R&D and $200k in raised capital—it lacks traditional financial projections, a specific fundi…
Key takeaways
- The company uses engineered microorganisms to turn dairy byproducts into biodegradable plastic resins and colorants (Slide 4).
- Ourobio has reached Technology Readiness Level (TRL) 3/4, co-producing PHB and colorants from raw whey (Slide 6).
- The business model includes both manufacturing and licensing of their biomanufacturing abilities (Slide 5).
- Traction includes 1000+ hours of market discovery resulting in initial MOUs and offtake agreements (Slide 6).
- The founders have bootstrapped $400k for R&D and raised an additional $200k in capital (Slide 6).
- The technical process is protected by pending Patent and PCT technology with a strategy for a larger patent family (Slide 6).
- The deck omits a specific dollar amount for a current funding round, instead asking for 'investor intros' and 'non-dilutive funding' (Slide 9).
- The team consists of two co-founders with backgrounds in chemistry and bioengineering from the University of Virginia (Slide 8).
Executive Summary: The Circular Bioeconomy Pitch
Ourobio’s teaser deck, dated May 2023, is a concise 10-slide presentation focused on the intersection of industrial waste management and sustainable materials. The company’s value proposition centers on a proprietary fermentation process that transforms dairy waste into high-value bioplastics and colorants. The deck is designed to establish technical credibility and market interest rather than provide a deep dive into unit economics or financial forecasting.
Slide 1: Title Slide
The deck opens with the Ourobio logo and the tagline "Catalyzing the circular bioeconomy." The visual identity is clean, using blue and green tones that reinforce the "bio" and "circular" themes. There is no mention of a specific funding round on the cover, identifying it clearly as a general teaser.
Slide 2: The Vision Statement
Slide 2 presents a high-level thesis: "Biotechnology is the sustainable alternative to petrochemistry." This serves as the 'why' behind the company, positioning Ourobio within the broader global shift away from fossil-fuel-based plastics. It is a standard industry-context slide that sets the stage for the specific problem they solve.
Slide 3: The Mission and Process Overview
This slide introduces the core objective: helping manufacturers and brands transition to the bioeconomy. It outlines a three-step visual flow: 1) Organic waste from industry, 2) Ourobio’s proprietary bioprocesses (engineered microorganisms), and 3) Low-footprint, complementary biomaterials. This slide is effective because it defines the company's role as the bridge between waste and product.
Slide 4: Technical Specificity - The Dairy Focus
Slide 4 narrows the focus to the dairy industry. It explicitly states that their technology turns dairy byproducts into "bio-based, biodegradable plastic resins and colorants in a single fermentation process." The mention of a "single fermentation process" is a critical technical differentiator, as producing two distinct outputs (resin and colorant) simultaneously suggests significant efficiency gains over traditional methods.
Slide 5: The Business Model and Value Chain
Ourobio defines itself as a "manufacturer and licensor." The slide features a linear diagram showing the flow from Farms to Industrial Processors, then to Ourobio, followed by Converters, Brands, and End Users. It also highlights the circularity of the model, showing "Recycling" and "Composting" loops that return materials to the start of the chain. This slide clarifies that Ourobio sits in the middle of the supply chain, providing the raw material (or the tech to make it) to converters who then supply brands.
Slide 6: Accomplishments and Traction
This is the strongest slide in the deck for building investor confidence. It lists four key milestones:
R&D Progress: Reached TRL 3/4, successfully co-producing PHB and colorants from raw whey. · Market Discovery: 1000+ hours of discovery leading to the first MOUs and offtake agreements. · Intellectual Property: Patent and PCT pending technology with a clear IP strategy. · Capital Efficiency: $400k bootstrapped for R&D and $200k raised, alongside 3+ year relationships with partners.
The slide also includes a badge from StartUs Insights naming them one of the "5 Top Biomaterials Startups to Watch in 2022."
Slide 7: The Product Pipeline
Slide 7 illustrates the "elaborate vision" for their product roadmap. It starts with "Blue colorant and resin" (likely their current MVP) and expands into "Biodegradable plastic blends," "Portfolio of PHA co-polymers," "Multi-colored Bioplastics," and "Novel, performance-enhancing additives." This demonstrates that the technology is a platform capable of producing a wide range of materials beyond their initial offering.
Slide 8: The Team
Kobe Rogers (COO): B.S. Chemistry, Alumni Chair of Alpha Chi Sigma, 5 years in biochemistry R&D. · Alec Brewer (CEO): B.S. Bioengineering (UVA), Co-founder of ValleyDAO, 5 years of entrepreneurship experience.
The right side of the slide is crowded with logos from accelerators and partners, including Virginia Tech, Clinton Global Initiative, Plug and Play, EPA, and MassChallenge. This "logo soup" effectively communicates that the founders have been highly active in the startup ecosystem and have received significant institutional validation.
Slide 9: The "How to Help" (The Ask)
Interestingly, this slide does not ask for a specific dollar amount. Instead, it lists three needs: 1) Access to organic waste streams, 2) Non-dilutive funding and investor intros, and 3) Connections to converters and brands. This reinforces the "teaser" nature of the deck, suggesting it is used for networking and early-stage conversations rather than a hard close on a priced round.
Slide 10: Contact Information
The final slide provides direct email addresses for both founders and a "Thank You" message. It is standard and professional.
What Ourobio Does Well
Technical Clarity: The deck does an excellent job of explaining a complex biological process in simple terms. The distinction of the "single fermentation process" for two outputs is a clear competitive advantage that is highlighted early and often.
Validation: For a pre-seed or seed-stage company, the amount of external validation shown on Slide 8 (accelerators) and Slide 6 (TRL levels and MOUs) is impressive. It suggests the founders are disciplined about seeking non-dilutive support and market feedback.
Visual Storytelling: The use of circular diagrams and flowcharts helps the reader visualize exactly where Ourobio fits into a very large and complex global supply chain.
What is Missing from the Deck
Financial Projections: There is no mention of revenue targets, margins, or the cost-plus model for their resins. Investors in the hardware/biotech space need to see a path to price parity with petroleum-based plastics.
Competitive Landscape: The bioplastics space is crowded (e.g., Danimer Scientific, RWDC Industries). The deck does not address how Ourobio’s PHA/PHB compares to existing biopolymers in terms of performance or price.
The Ask: While they ask for "investor intros," the lack of a specific funding target or a "use of proceeds" breakdown makes it difficult for an investor to gauge the scale of the opportunity or the current runway.
Founder Takeaways
Focus on the 'Unfair Advantage': If your tech does two things at once (like Ourobio's resin + colorant), make that the centerpiece of your technical slides. It is a shorthand for efficiency that investors understand.
Leverage Ecosystem Logos: If you have participated in reputable accelerators or won grants (EPA, MassChallenge), display them prominently. In deep tech, these logos act as a proxy for technical due diligence that the investor may not be qualified to perform themselves.
TRL Language: Using "Technology Readiness Level" (TRL) terminology is highly effective when pitching to climate-tech or deep-tech investors. It provides a standardized framework for understanding how close a lab concept is to commercial reality.
Frequently asked questions
- What is Ourobio's core technology?
- Ourobio develops engineered microorganisms designed to convert industrial byproducts, specifically dairy waste like raw whey, into biomaterials. Their proprietary bioprocess is unique because it produces both biodegradable plastic resins (PHB) and natural colorants in a single fermentation step, potentially reducing costs and environmental impact compared to traditional two-step processes.
- What stage of development is the company in?
- According to slide 6, the company is at Technology Readiness Level (TRL) 3/4. They have successfully co-produced PHB and colorants from raw whey in a lab setting. They have also moved into the commercial validation phase, having conducted over 1000 hours of market discovery and secured initial MOUs and offtake agreements with prospective partners.
- How does Ourobio plan to make money?
- Ourobio employs a dual business model as stated on slide 5. They intend to operate as both a manufacturer of biomaterials and a licensor of their proprietary biomanufacturing technology. This allows them to capture value through direct sales to converters and brands, while also scaling through IP licensing to existing industrial processors.
- Who are the founders of Ourobio?
- The company was co-founded by Kobe Rogers (COO) and Alec Brewer (CEO). Rogers holds a B.S. in Chemistry and has five years of independent biochemistry R&D experience. Brewer holds a B.S. in Bioengineering from UVA and has five years of experience in entrepreneurship and small business management.
- What is missing from this pitch deck?
- As a teaser deck, it lacks several standard components found in a full series A or Seed deck. There are no financial projections, no detailed breakdown of the total addressable market (TAM), no competitive landscape analysis, and no specific 'ask' regarding the amount of capital they are currently seeking to raise.
